Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cronos Group Inc (CRON) vs Marqeta Inc (MQ) Price & Performance

Cronos Group IncTrade
Marqeta IncTrade

Price performance (Past 24H)

Key statistics

Cronos Group Inc vs Marqeta Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Marqeta Inc trades at $17.86 (market cap $1.82B). The key difference: Marqeta Inc is the larger of the two by market cap, and Cronos Group Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Marqeta Inc for 44 Days on average.

CRONMQ
Market Cap
$1.18B$1.82B
Volume
968,0371,126,466
Sector
HealthTechnology
52-Week High
$3.55$20.32
52-Week Low
$2.30$15.04
Typical Hold Time
22 Days44 Days
Enterprise Value
$387.62M$1.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cronos Group Inc

CRON trades at $3.24, down 1.37% today amid a bearish technical signal. Recent quarterly earnings show beats in Q1 and Q2 2026, with revenue growth from $118M in 2024 to $147M in 2025. The company reported a net loss of $9.45M in 2025 but projects a profit of $70M for 2026. Analyst sentiment is mixed with a 20% buy rating. News highlights focus on international expansion and a recent Investor Day outlining growth strategies.

Outlook is cautiously optimistic given projected profitability in 2026 and strong cash reserves, but risks include sustained negative cash flow and competitive pressures. The stock's valuation metrics like P/E of 16.95 and P/S of 6.84 suggest moderate pricing relative to peers, though high EV/EBITDA of 43 indicates premium expectations.

Marqeta Inc

MQ trades at $17.06, up 3.08% today, with a bullish technical signal from moving averages. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue is projected to grow to $677 million in 2026, and net income turned positive in 2024 before a slight loss in 2025. Recent partnerships with BVNK for stablecoin-card infrastructure and Google for wallet expansion highlight strategic growth initiatives.

MQ shows improving fundamentals with revenue growth and recent profitability, but high valuation ratios (P/E of 193.83) pose a risk. The consensus price target of $11.38 suggests potential downside, though some analysts see upside to $18.00. Key risks include contract renewals in Q3 2026 and competitive pressures in the fintech sector. The stock's outlook hinges on execution of growth initiatives and sustained earnings improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cronos Group Inc

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Read more on CRON →

About Marqeta Inc

Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.

Read more on MQ →